April 21 (Reuters) - Nippon Shinyaku Co Ltd 4516.T:
NS PHARMA: FDA GRANTS ORPHAN DRUG DESIGNATION TO NS-229 FOR TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.